- $6.73bn
- $7.57bn
- $1.48bn
US STOCKS ON THE MOVE-Meta, Marvell Technology, Insmed
U.S. STOCKS ON THE MOVE-Accenture, Arhaus, Alkermes
Alkermes rises after positive early-stage ADHD drug data
Alkermes Plc reports results for the quarter ended June 30 - Earnings Summary
Brief: Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 2 At Sleep 2026
Brief: Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
Alkermes rises as it starts late-stage trials of sleep disorder drug
Reports $384.5 Million Revenues For Q4 2025 - SEC Filing
Brief: Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market
Pharma companies left out of Trump's drug-pricing deals look for way in
U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla
U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin
U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge
Alkermes rises as narcolepsy drug gets FDA breakthrough tag
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Deals of the day-Mergers and acquisitions